| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Nov 7, 2018 | EBS Emergent Biosolutions Inc. | Zoon Kathryn C62 | Director | Sell | 4,242 | $69.74 | $295,855.65 | -9.8% | |
| Nov 7, 2018 | EBS Emergent Biosolutions Inc. | Richard Ronald | Director | Sell | 7,893 | $70.00 | $552,510.00 | -27.4% | |
| Nov 7, 2018 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 38,819 | $110.13 | $4,275,299.78 | -6.7% | |
| Nov 7, 2018 | NBIX Neurocrine Biosciences Inc | Lloyd-Smith Malcolm49 | Chief Regulatory Officer | Sell | 9,000 | $110.01 | $990,095.76 | -22.7% | |
| Nov 6, 2018 | LLY Eli Lilly & Co | Lilly Eli & Co | 10% Owner | Sell | 700,000 | $14.00 | $9,800,000.00 | -18.2% | |
| Nov 6, 2018 | EBS Emergent Biosolutions Inc. | Joulwan George A | Director | Sell | 4,058 | $68.45 | $277,784.30 | -13.4% | |
| Nov 6, 2018 | EBS Emergent Biosolutions Inc. | Harsanyi Zsolt | Director | Sell | 8,000 | $68.90 | $551,193.60 | -19.1% | |
| Nov 5, 2018 | TEVA Teva Pharmaceutical Industries Ltd | McClellan Michael James | EVP, Chief Financial Officer | Sell | 346 | $22.73 | $7,865.13 | -2.9% | |
| Nov 5, 2018 | BCRX Biocryst Pharmaceuticals Inc | Powell Lynne | Senior VP - CCO | Sell | 100 | $8.00 | $800.00 | -1.1% | |
| Nov 5, 2018 | BCRX Biocryst Pharmaceuticals Inc | Staab Thomas R II | Senior Vice President And CFO | Sell | 215 | $8.00 | $1,720.00 | -0.2% | |
| Nov 5, 2018 | ESPR Esperion Therapeutics, Inc. | Boxer Capital, LLC79 | 10% Owner | Sell | 100,000 | $56.38 | $5,638,342.60 | -1.1% | |
| Nov 2, 2018 | BCRX Biocryst Pharmaceuticals Inc | Staab Thomas R II | Senior Vice President And CFO | Sell | 10,856 | $7.84 | $85,089.68 | -3.8% | |
| Nov 2, 2018 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,000 | $37.51 | $37,510.00 | -100% | |
| Nov 2, 2018 | NBIX Neurocrine Biosciences Inc | Lyons Gary A54 | Director | Sell | 15,000 | $114.41 | $1,716,213.00 | -5.8% | |
| Nov 2, 2018 | BCRX Biocryst Pharmaceuticals Inc | Powell Lynne | Senior VP - CCO | Sell | 1,000 | $8.00 | $8,000.00 | -10.4% | |
| Nov 2, 2018 | PCRX Pacira Biosciences, Inc. | Riker Lauren Bullaro76 | Vice President, Finance | Sell | 1,000 | $54.35 | $54,350.00 | -8.7% | |
| Nov 2, 2018 | EBS Emergent Biosolutions Inc. | Havey Adam | EVP, Business Operations | Sell | 8,179 | $64.25 | $525,534.50 | -12.3% | |
| Nov 2, 2018 | ESPR Esperion Therapeutics, Inc. | Newton Roger S | Director | Sell | 2,827 | $50.07 | $141,548.52 | -0.2% | |
| Nov 1, 2018 | HROW Harrow, Inc. | Kammer Robert J | - | Sell | 10,000 | $4.21 | $42,100.00 | -1.1% | |
| Nov 1, 2018 | PAHC Phibro Animal Health Corp | Warras Dean J | Pres Animal Health &Nutr N.a. | Sell | 10,000 | $42.84 | $428,414.00 | -50.5% | |
| Nov 1, 2018 | MRK Merck & Co., Inc. | Schechter Adam H | EVP &Pres-global Human Health | Sell | 277,879 | $73.81 | $20,510,945.05 | -65.7% | |
| Nov 1, 2018 | BCRX Biocryst Pharmaceuticals Inc | Powell Lynne | Senior VP - CCO | Sell | 1,544 | $7.51 | $11,595.44 | -15.2% | |
| Oct 31, 2018 | MRK Merck & Co., Inc. | Watson Ashley | SVP Chief Ethics &Com Officer | Sell | 47,036 | $74.33 | $3,496,157.66 | -82.8% | |
| Oct 31, 2018 | AMRN Amarin Corp Plc\uk | Ketchum Steven B | Chief Scientific Officer | Sell | 17,042 | $20.74 | $353,453.86 | -2.4% | |
| Oct 31, 2018 | AMRN Amarin Corp Plc\uk | Kennedy Joseph T | General Counsel | Sell | 23,307 | $20.74 | $483,362.25 | -5.1% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.